Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Liposome-loaded Urea
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kato Wins FDA Approval for Human Studies of Drug for Retinal Disorders
Details : The approval allows Kato to study the efficacy of Resolv ER, first-in-class patented formulation therapeutic drug is intended to separate the vitreous from the retina on VMA which may lead to retinal tears, retinal detachment, and macular holes.
Product Name : Resolv ER
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 16, 2022
Lead Product(s) : Liposome-loaded Urea
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
